Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26492955 | 1.00 | GNAI3 (0.44) | GNAI3GNAO1GNAI1SIGMAR1NPC1 | |
| SCHEMBL18220631 | 1.00 | GNAI3 (0.44) | GNAI3GNAO1GNAI1SIGMAR1NPC1 | |
| SCHEMBL16500386 | 0.92 | GNAI3 (0.53) | GNAI3GNAO1GNAI1PAOX | |
| SCHEMBL22822213 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SIGMAR1DNM1 | |
| SCHEMBL24016791 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SIGMAR1DNM1 | |
| SCHEMBL23383576 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SIGMAR1DNM1 | |
| SCHEMBL24411165 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SIGMAR1DNM1 | |
| SCHEMBL20623315 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SIGMAR1DNM1 | |
| SCHEMBL21784117 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SIGMAR1DNM1 | |
| SCHEMBL21657387 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SIGMAR1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452934-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | Providence Therapeutics Holdings Inc. (CA) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024156053-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2024-08-02 | — | — | WO | disclosed |
| EP-4402121-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118317944-A | Acyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118234707-A | Cyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-06-03 | — | — | US | disclosed |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-06-03 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-22 | — | — | US | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885 |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885 |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | GNAI3 2887/4885GNAO1 4561/4885GNAI1 3468/4885 |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885 |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885 |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAI3 1599/4885GNAO1 3550/4885GNAI1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.